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ABSTRACT 
New derivatives are designed as target directed MAO-B Inhibitors for medical care of the patients for neurodegenerative disorder. 
Molecular design and estimated pharmacokinetic properties have been evaluated by using Inventus v 1.1 software. The binding 
mode of the proposed compounds with target protein i.e. 1S2Q was evaluated and the resulting data from docking studies explained 
that newly designed derivatives have high and better affinity towards target protein. Based on these properties, the binding affinities 
are used for speeding up drug discovery process by eliminating less potent compounds from synthesis. 
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INTRODUCTION 
Computer aided drug design (CADD) is the process 
which facilitates computational approaches and 
resources that are used in Design and Discovery of new 
therapeutic agents.
1
 The discovery and development of 
new drugs are long, tedious, complex and costly 
process.
2
 It is a typical drug discovery cycle, which takes 
10-15 years and million dollar currency to introduce in 
marketplace. That’s why CADD has been widely used in 
Pharmaceutical field to accelerate the designing process 
in most efficient way.
3 
MAO-B Inhibitor as therapeutic target 
Parkinson’s disease is a neurodegenerative disorder of 
the brain resulting in Dopamine deficiency caused by the 
progressive death of dopaminergic neurons. Selegiline is 
first class drug which inhibits Dopamine metabolism but 
its therapeutic effects are compromised by its neurotoxic 
metabolites. To overcome this obstacle, a novel MAO-B 
inhibitor Rasagiline was developed. It is biotransfered to 
aminoindan, a non-amphetamine compound. It is 
effective as monotherapy or adjunct to L-dopa for 
patients with Parkinson’s patients.4 
MATERIAL AND METHODS 
Computing is used in various ways in drug discovery. 
Important example includes QSAR and Structure Based 
methods. Here we focused on Structure based methods. 
These methods show increasing utility for the discovery 
of the lead compounds and for refinement of lead 
compounds and for re-engineering of drug to overcome 
certain types of resistance. It becomes important in the 
rapid growth in structural data and determined as part of 
a focused drug-discovery effort with a well-
characterized target.
5 
Here, Structure based Drug design approaches were 
employed to develop potent MAO-B inhibitors for the 
Parkinson drug candidate. 
Overview of the Process 
Methods used to design inhibitors ranged from graphical 
visualization of the ligand in the binding site cavity to 
calculation of relative binding affinities using molecular 
mechanics. It is important to understand the interaction 
of the ligand with its receptor protein by examining the 
3-D structure of the protein target in complex with the 
ligand. It helps in studying the interaction with the 
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protein, while modifying the analogues with the receptor 
or enzyme for better results.With the knowledge of the 
structure of target-protein-ligand complex, the structure 
activity relationship of compounds, suggest new 
analogues to synthesize and develop new ligand 
moieties. This methodology is known as Structure based 
Drug Design.
6 
Steps involved in structure based drug design 
 
Target Protein Selection 
The processes of structure based drug design often 
proceed through multiple cycles. The first cycle includes 
cloning, purification and structure determination of the 
target protein by one of three principle methods:- 
(1) X-ray crystallography (2) NMR  (3) Homology 
Modeling 
The ideal target macromolecule for Structure based drug 
design is one that is closely linked to human disease and 
binds a small molecule in order to carry out a function. 
RCSB-PDB (Research Collaboratory for Structural 
Bioinformatics-Protein Data Bank) is the most common 
source of crystal structure and structural information for 
drug design. The crystal structure of MAO-B in complex 
with Rasagiline was selected for this study and obtained 
from RCSB-PDB with PDB ID- 1S2Q. It has total 2 
Chains, Resolution- 2.07Å. The structure is shown in 
figure. Using the structural information obtained through 
PDB, the 3-D structure of target was then prepared for 
drug design program. 
 
Figure 1: Crystal structure of MAO-B in complex 
with N-propargyl-1(R)-aminoindan (Rasagiline) 
Energy Minimization 
In silico processing of protein structure starts with 
energy minimization, this tool uses steepest descent 
(SD) and Conjugate gradient (CG) algorithm to 
minimize the potential energy of protein molecule. 
 
 
 
Figure 2: Snapshot of Energy Minimization 
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Clash Optimization 
Many times energy minimizes is unable to remove all 
clashes from protein structure which may create 
difficulty in outcome during Docking of Protein and 
Ligand inhibitor. It is based on Monte Carlo technique is 
used to remove clashes from protein structure. It can fix 
the number of cycles; we usually run 25-30 cycles and 
observe the effects of optimization process. 
 
 
 
Figure 3: Snapshot of Clash Optmization 
Binding Pocket Detection 
In Inventus v1.1 software, the active site detection in a 
protein structure is based on its geometry like volume, 
depth. We identified maximum 10 active sites with 
ranking order and selected the best active site. We also 
compared the active site residues of Reference Ligand 
and found that each of the residues of active site lies in 
Cavity 2. So Cavity 2 is considered as active site or 
binding pocket. The active site residue within the 
distance of 5Å were-  GLY 58, TYR 60, PHE 168, LEU 
171, CYS 172, ILE 198, ILE 198, GLN 206, TYR 326, 
LEU 328, PHE 343, TYR 398, TYR 435. 
 
Figure 4: Active site residues of 1S2Q with 
Rasagiline. 
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High Throughput Screening 
Virtual screening process needs the speed and accuracy, 
where speed is the time required in screening and 
accuracy is finding true positives from the screened 
compound pool of library. 
It is based on the protocol developed to remove the false 
positive from the screened molecules. Molecule can be 
screened using customized library as well as embedded 
library.
 
 
Figure 5:  List of Screened compounds by Hits-Gen 
Molecular Docking 
It starts with the knowledge of active sites or with the 
information about the ligand receptor complex. It 
predicts the non-covalent binding of macromolecule 
(receptor) and a small molecule (ligand). The key 
characteristic of good docking program is its ability to 
reproduce experimental binding poses of ligand. 
 Docking of small molecules to receptor structures has 
become increasingly   important in the context of drug 
discovery.
7-9
 Over the past few years a number of 
methods have been developed for performing 
(relatively) fast predictions for a series of molecules 
regarding their ability to bind to a protein binding site.
10
 
Analogue design is usually defined as the modification 
of a drug molecule in order to prepare a new molecule 
showing chemical and biological similarity with the 
original model compound. In this study Rasagiline was 
selected as reference molecule and its structure was 
obtained from PubChem. In the first step, the reference 
molecule was docked into the active site and its binding 
affinity was noted i.e. (-13.54 kcal/mol). The reference 
molecule was modified to develop more potent 
molecules/compounds based on the data of high 
throughput screening and SAR information. 
Pose prediction versus affinity prediction  
Technically, the placement of the molecules in the 
region of interest (e.g. the receptor-binding site) is 
referred to as ‘docking’, whereas the prediction of 
affinity is referred to as ‘scoring’. The distinction 
between docking and scoring defines also the two major 
technical challenges faced by docking programs: to 
predict the binding mode of a molecule correctly 
(herewith also referred to as ‘pose prediction’, where 
‘pose’ refers to the orientation and conformation of a 
molecule at the receptor binding site)
11
 and to predict the 
binding affinity of compounds (or to produce a relative 
rank-ordering for a number of compounds) in a reliable 
manner. 
12
  
In this study, prepared protein and all analogues were 
subjected to docking using Novo-Docker module of 
Inventus v1.1 software to carry out the protein analogue 
interaction studies. 
RESULT AND DISCUSSION 
By using Structure based drug design, we have designed 
15 analogues. Docking was performed for analysis of 
protein ligand interactions using Inventus v1.1 software 
and results are shown in table 1. 
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Table 1: Docking results of designed analogues 
S.No.                          Compounds    Properties 
1 
 
BioAff: -14.12 
M.W.: 206.25 
HBA : 4 
HBD : 2 
Log P : 2.05 
2 
      Chemical Formula : C10H9NO 
BioAff: -14.10 
M.W. : 159.19 
HBA : 2 
HBD : 1 
Log P : 1.63 
3 
                             
Chemical Formula: C17H17NO3 
BioAff: -14.12 
M.W. : 283.33 
HBA : 4 
HBD : 1 
Log P : 2.55 
4 
 
                    Chemical Formula: C16H16BrN 
BioAff: -14.01 
M.W. : 302.22 
HBA : 1 
HBD : 1 
Log P : 3.12 
5 
 
                    Chemical Formula :C16H17N 
BioAff: -14.12 
M.W. : 223.32 
HBA : 1 
HBD : 1 
Log P : 3.58 
6 
 
                     Chemical Formula: C17H19N 
BioAff: -14.01  
M.W. :  237.35 
HBA : 1 
HBD : 1 
Log P : 3.70 
7 
                      Chemical Formula: C14H21N 
BioAff : -14.12 
M.W. : 203.33 
HBA : 1 
HBD : 1 
Log P: 3.61 
8 
                     
Chemical Formula: C13H18BrN 
BioAff : -14.12 
M.W. : 268.20 
HBA : 2 
HBD : 2 
Log P : 1.53 
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9 
                   
Chemical Formula: C13H18FN 
BioAff: -14.12 
M.W. : 207.29 
HBA : 4 
HBD : 2  
Log P : 2.05 
 
10 
 
                         Chemical Formula:C11H12N2 
BioAff: -14.09 
M.W.: 172.23 
HBA : 1 
HBD : 1 
Log P : 2.70 
11 
               
Chemical Formula: C11H14N2O2 
BioAff: -14.12 
M.W.: 187.28 
HBA : 1 
HBD : 1 
Log P : 3.01 
12 
                 
Chemical Formula: C14H19NO 
BioAff: -14.01 
M.W.: 191.24 
HBA : 1 
HBD : 1 
Log P : 2.92 
13 
                        
Chemical Formula: C15H15N 
BioAff: -14.01 
M.W.: 272.34 
HBA : 4 
HBD : 1 
Log P : 2.84 
14 
 
                         Chemical Formula:C12H14ClN 
BioAff: -14.01 
M.W.: 277.36 
HBA : 2 
HBD : 1 
Log P : 3.46 
15 
 
     Chemical Formula: C12H14FN 
BioAff: -14.12 
M.W.: 291.39 
HBA : 2 
HBD : 1 
Log P : 3.92 
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After molecular docking, we have analyzed the ADME 
(structure only) properties of the all designed analogues 
by using pharmopredicta module of inventus. The key 
features of this module, which were used in our study, 
are described below:  
ADME (Structure Based)  
1) Human Absorption, FDp (%) binned  
Results are classified as  
• Low (0-33% absorbed)  
• Medium (33-64% absorbed)  
• High (67-100% absorbed)  
2) Caco-2 Permeability (A→ B or apical to basolateral)  
Peff at pH 7.4 (cm/s)  
Additional output data provided by pkEXPRESS plus 
module only:  
3) Caco-2 Permeability (B→ A or basolateral to apical)  
Peff at pH 7.4 (cm/s)  
4) Efflux at pH 7.4 (0 if ≤ 5.3, 1 if >5.3)  
5) Blood brain barrier permeability (0 if no penetration, 
1 if penetration)  
6) Protein binding (0 if ≤ 85% or 1 if > 85%)  
7) Volume of Distribution at steady state (VDSS; liters) 
  
Table 2: Caco-permeability and efflux parameters of designed compounds 
Compound Caco74ab Caco 74ab 
Confidence 
Caco74 ba Caco 74ba 
confidence 
efflux Efflux 
Confidence 
Reference 4.90E-05 High 5.73E-05 High 0 High 
Analog 1 4.90E-05 Low 5.67E-05 High 0 High 
Analog 2 4.90E-05 High 5.73E-05 High 0 High 
Analog 3 4.90E-05 Medium 5.43E-05 High 0 High 
Analog 4 4.90E-05 Medium 5.73E-05 High 0 High 
Analog 5 4.90E-05 Medium 5.63E-05 High 0 High 
Analog 6 4.90E-05 Low 5.06E-05 High 0 High 
Analog 7  4.90E-05 Low 4.79E-05 High 0 High 
Analog 8  4.90E-05 Low 4.80E-05 High 0 High 
Analog 9 4.90E-05 Medium 4.54E-05 High 0 High 
Analog 10 4.90E-05 Medium 5.73E-05 High 0 High 
Analog 11 4.90E-05 Medium 2.66E-05 High 0 High 
Analog 12 4.90E-05 Medium 5.43E-05 High 0 High 
Analog 13 4.90E-05 Low 5.06E-05 High 0 High 
Analog 14 4.90E-05 Medium 4.54E-05 High 0 High 
Analog 15 4.90E-05 Medium 4.54E-05 High 0 High 
 
Table 3: bbb, fdp, vdss parameters of designed compounds 
Compound  
ID 
BBB BBB 
Conf. 
Fdp Fdp conf. Probind Probind 
Conf. 
Vdss Vdss 
Conf. 
Reference 1 High High High 1 High 1000 High 
Analog 1 1 Low High Low 0 Medium 1000 High 
Analog 2 1 High High Medium 0 Medium 100 High 
Analog 3 1 Low High Low 0 Medium 1000 High 
Analog 4 1 High High Medium 1 Medium 10 High 
Analog 5 1 Low High Low 1 High 1000 High 
Analog 6 1 Low High Low 1 High 1000 High 
Analog 7 1 Low High Low 1 Medium 1000 High 
Analog 8 1 Low High Low 0 Low 1000 High 
Analog 9 1 High High Medium 1 Medium 10 High 
Analog 10 1 High High Medium 1 Medium 10 High 
Analog 11 1 High High Medium 1 Medium 100 High 
Analog 12 1 High High Medium 1 Medium 1000 High 
Analog 13 1 High High Medium 1 Medium 10 High 
Analog 14 1 High High Medium 1 Medium 1000 High 
Analog 15 1 High High Medium 1 Medium 10 High 
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A large percentage of the proposed analogs were 
eliminated by considering Lipinski rule of five and by 
evaluating their physicochemical properties, binding 
affinities based on docking and ADME properties. The 
analogues having similar pharmacokinetic properties as 
reference and with higher docking scores i.e. compound 
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15  have been 
considered as the potent analogues, where the reference 
drug rasagiline has shown the docking score 13.54 and 
docking scores of other ligands was shown in the Table 
1.  
Binding interactions of the designed leads are described 
as follows:  
Compound 1: 6, 7-dihydro-5H-cyclopenta[b]pyridin-
7-yl ethylcarbamate 
 
Figure 6: Binding mode of compound 1 with 1S2Q 
The proposed binding mode of compound 1 revealed an 
affinity value of –14.12 kcal/mol. Residues SER 57, 
TYR 58, CYS 170, TYR 186, ILE 196, GLN 204, VAL 
292, CYS 395, GLY 432, TYR 433, MET 434 shows 
electrostatic interaction with compound 1 and 
hydrophobic cleft was formed by LEU 54, GLY 55, 
GLY 56, LEU 169, LYS 294, TYR 324, MET 339, PHE 
341, TYR 396.  
Compound 4: (R)-N-benzyl-6-bromo-2, 3-dihydro-1-
H-inden-1- amine 
 
Figure 7: Binding mode of compound 4 with 1S2Q 
The proposed binding mode of compound 4 revealed an 
affinity value of –14.01 kcal/mol. Residues SER 57, 
TYR 58, CYS 170, TYR 186, ILE 196, GLN 204, GLY 
432, TYR 433, MET 434 shows electrostatic interaction 
with compound 4 and hydrophobic cleft was formed by 
LEU 54, GLY 56, LEU 169, TYR 324, MET 339, PHE 
341, TYR 396. 
Compound 5: (R)-N-Benzyl-2,3-dihydro-1H-1inden-
1-amine 
 
Figure 8: Binding mode of compound 5 with 1S2Q 
The proposed binding mode of compound 5 revealed an 
affinity value of –14.12 kcal/mol. Residues SER 57, 
TYR 58, CYS 170, TYR 186, ILE 196, GLN 204, VAL 
292, CYS 395, GLY 432, TYR 433, MET 434 shows 
electrostatic interaction with compound 5 and 
hydrophobic cleft was formed by GLY 56, LEU 169, 
LYS 294, TYR 324, MET 339, PHE 341 and TYR 396. 
Compound 6: (R)-N-benzyl-6-methyl-2,3-dihydro-
1H-inden-1-amine 
 
Figure 9: Binding mode of compound 6 with 1S2Q 
The proposed binding mode of compound 6 revealed an 
affinity value of –14.01 kcal/mol. Residues SER 57, 
TYR 58, CYS 170, TYR 186, ILE 196, CYS 395, GLY 
432, TYR 433, MET 434 shows electrostatic interaction 
with compound 6 and hydrophobic cleft was formed by 
GLY 55, GLY 56, LEU 169, LYS 294, TYR 324, MET 
339 and PHE 341. 
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Compound 7: (R)-N-butyl-6-methyl-2,3-dihydro-1H-
inden-1-amine 
 
Figure 10: Binding mode of compound 7 with 1S2Q 
The proposed binding mode of compound 7 revealed an 
affinity value of –14.12 kcal/mol. Residues SER 57, 
TYR 58, CYS 170, TYR 186, ILE 196, GLN 204, CYS 
395, GLY 432, TYR 433, MET 434 shows electrostatic 
interaction with compound 7 and hydrophobic cleft was 
formed by LEU 54, GLY 55, GLY 56, LEU 169, LYS 
294, PHE 341 and TYR 396. 
Compound 8:    (R)-6-bromo-N-butyl-2,3-dihyro-1H-
inden-1-amine 
 
Figure 11: Binding mode of compound 8 with 1S2Q 
The proposed binding mode of compound 8 revealed an 
affinity value of –14.12 kcal/mol. Residues SER 57, 
TYR 58, CYS 170, TYR 186, ILE 196, GLN 204, VAL 
292, CYS 395, GLY 432, TYR 433, MET 434 shows 
electrostatic interaction with compound 8 and 
hydrophobic cleft was formed by LEU 54, GLY 55, 
GLY 56, LEU 169, LYS 294, TYR 324, MET 339, PHE 
341, TYR 396. 
Compound 9:    (R)-N-butyl-5-fluoro-2,3-dihyro-1H-
inden-1-amine 
 
Figure 12: Binding mode of compound 9 with 1S2Q 
The proposed binding mode of compound 9 revealed an 
affinity value of –14.12 kcal/mol. Residues SER 57, 
TYR 58, CYS 170, TYR 186, ILE 196, GLN 204, VAL 
292, CYS 395, GLY 432, TYR 433, MET 434 shows 
electrostatic interaction with compound 9 and 
hydrophobic cleft was formed by LEU 54, LEU 169, 
LYS 294, TYR 324, PHE 341 and TYR 396. 
Compound 10: (R)-N-(prop-2YN-1-YL)-6,7-dihydro-
6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine 
 
Figure 13: Binding mode of compound 10 with 1S2Q 
The proposed binding mode of compound 10 revealed 
an affinity value of –14.09 kcal/mol. Residues SER 57, 
TYR 58, CYS 170, TYR 186, ILE 196, GLN 204, VAL 
292, CYS 395, GLY 432, TYR 433, MET 434 shows 
electrostatic interaction with compound 10 and 
hydrophobic cleft was formed by GLY 56, LEU 169, 
LYS 294, TYR 324 and PHE 341. 
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Graphical representation of different parameters of lead compounds:  
 
Figure 14: BBB values of lead compounds 
 
Figure 15: Caco 74ba values of lead compound 
 
Figure 16: Vdss values of lead compounds 
 
Figure 17: Caco74ab values of lead compounds 
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CONCLUSION 
Some novel derivatives were designed and molecular 
docking study was performed for prediction of MAO-B 
inhibitory activity. The binding mode of the proposed 
compounds with the target protein ie. 1S2Q was 
evaluated and the resulting data from the docking 
studies explained that all the newly designed derivatives 
had high and better affinity towards the target protein 
compared to rasagiline as a reference ligand. Among 15 
derivatives, all the compounds have better bioaffinity 
values. Docking studies shows that the electrostatic and 
hydrophobic interactions with target molecule. It reveals 
that all the compounds occupy the same binding pocket 
in the active sites.  
Compounds 4, 5, 6, 7, 10, 11, 14, 15 show the highest 
values of log p as compared to the target protein. It is 
also predicted the structure based pharmacokinectic 
properties of all designed compounds by using 
pharmopredicta module of inventus v1.1 software and 
found that most of the final leads were similar as 
reference. 
Compounds 2, 4, 9, 10, 11, 12, 13, 14, 15 shows the 
better values and conformation for BBB penetration. 
The results shows that before synthesis, biological 
activity testing and clinical trials of new analogues, 
these drug designing methods are used for speeding up 
drug discovery process by eliminating less potent 
compounds from synthesis. It may have chances to show 
the better results than rasagiline in laboratory as well, 
therefore it could be used for future design, optimization 
and investigation to produce more effective analogues. 
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